Results 51 to 60 of about 757 (146)

Association of eosinopenia with worsening prognosis in hospitalized Azvudine-treated COVID-19 patients: a retrospective cohort study

Frontiers in Immunology, 2023
BackgroundCurrent guidelines prioritize the use of Azvudine in Coronavirus Disease 2019 (COVID-19) patients, while biomarkers for prognosis in Azvudine-treated COVID-19 patients are still lacking.
Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Xiaomin Wang, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Qian Zhou, Qian Zhou, Qian Zhou, Qian Zhou, Qian Zhou, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Rui Wei, Rui Wei, Furong Zeng, Furong Zeng   +25 more
doaj   +1 more source

Composite outcome of oral azvudine vs. nirmatrelvir-ritonavir in COVID-19 patients: a retrospective cohort study. [PDF]

Front Pharmacol
ObjectiveTo explore the effectiveness and safety of azvudine and nirmatrelvir-ritonavir in a real-world setting.MethodsThis retrospective cohort study included adult patients with confirmed COVID-19 who received azvudine or nirmatrelvir-ritonavir ...
Chen J, Liu Z, Liu R, Su C, Yang Y, Wang Z.   +5 more
europepmc   +2 more sources

Safety profile of azvudine in COVID-19 patients with renal impairment: a retrospective analysis. [PDF]

Front Pharmacol
Objective Azvudine (FNC), an antiviral drug approved in China for the treatment of Coronavirus disease 2019 (COVID-19) infection, has not yet established a well-defined safety profile in patients with renal impairment. This study aimed to evaluate the safety of using FNC in patients with renal impairment.
Zhang X, Qian J, Cui J, Luo Y, Huang S, Wen Z.   +5 more
europepmc   +2 more sources

DataSheet1_Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching.docx

, 2023
Background: Nirmatrelvir/ritonavir and azvudine have been approved for the early treatment of COVID-19 in China, however, limited real-world data exists regarding their effectiveness and safety.Methods: We conducted a retrospective cohort study involving
Xue-Peng Gong (17140423), Lu Zeng (686537), An-Hua Wei (5985029), Wen-Ting Zhang (1789032), Lin Gui (1958380), Juan Li (146180), Lu Wang (45927), Dong Liu (115204)   +7 more
core   +1 more source

Immunophenotyping characteristics and clinical outcome of COVID-19 patients treated with azvudine during the Omicron surge. [PDF]

Front Immunol
BackgroundLittle is known about immunophenotyping characteristics and clinical outcomes of COVID-19 patients treated with azvudine during the Omicron variant surge.MethodsThis study enrolled patients diagnosed with COVID-19 from December 2022 to February
Qiu M, Song X, Zhang Q, Zou S, Pang L, Nian X.   +5 more
europepmc   +2 more sources

Effectiveness and safety of azvudine in COVID-19: A systematic review and meta-analysis. [PDF]

PLoS One
Objective The aim of this study was to assess the effectiveness and safety of azvudine in treating coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Methods A search was carried out in PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until October 20, 2023.
Amani B, Amani B.
europepmc   +3 more sources

Effectiveness and Safety of Nirmatrelvir/Ritonavir (Paxlovid) Versus Remdesivir in COVID‐19: A Systematic Review and Meta‐Analysis of Retrospective Studies

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background and Aim Nirmatrelvir/ritonavir (Paxlovid) and remdesivir are antiviral agents that have been widely used in the management of patients with Coronavirus disease 2019 (COVID‐19). This systematic review and meta‐analysis were conducted to compare the clinical effectiveness and safety outcomes of Paxlovid and remdesivir among patients ...
Arash Akbarzadeh, Masoud Razeghian, Foruzan Hajiabadi, Parvaneh Dehghan, Sadegh Ahmadi‐Mazhin, Maliheh Eshaghzadeh, Mohsen Poursadeqiyan, Rouhollah Shabestan   +7 more
wiley   +1 more source

Real-world efficacy of oral azvudine in hospitalized patients with COVID-19: A multicenter retrospective cohort study

Journal of Infection and Public Health
Background: Azvudine has become a widely used treatment for COVID-19 in China. Our study aimed to assess the real-world efficacy of azvudine in hospitalized COVID-19 patients during the omicron variant surge.
Rui Han, Youhong Guan, Pulin Li, Min Tang, Guanghe Fei, Daxiong Zeng, Ran Wang   +6 more
doaj   +1 more source

Survival benefit and safety evaluation of probiotic supplementation in omicron‐infected patients: Real‐world evidence from a multicenter 12,615‐patient cohort

VIEW, Volume 7, Issue 4, August 2026.
Probiotic supplements have shown benefits in reducing all‐cause mortality among hospitalized patients with SARS‐CoV‐2 infection. Patients with severe illness or without antiviral treatment were more likely to use probiotic supplements. Probiotic supplements may be a promising adjunctive therapy for SARS‐CoV‐2 infection.
Mengzhao Yang, Shanshuo Liu, Junyi Sun, Fuwei Wang, Guangyun Zhu, Xinjun Hu, Guowu Qian, Yiqiang Yuan, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Zujiang Yu, Zhigang Ren   +14 more
wiley   +1 more source

A Review on Medicinal Chemistry and Biological Activity of Dihydropyrimidinones Against HIV

Archiv der Pharmazie, Volume 359, Issue 4, April 2026.
This article presents the latest advances in the development of dihydropyrimidinone (DHPM) derivatives as promising candidates against HIV. By exploring their interactions with essential viral targets and highlighting innovative compounds with potent antiviral activity, we provide an updated perspective on the opportunities for new antiretroviral ...
Debora I. Leite, Fernando B. Macedo, Murilo Marinho de C. Lima, Isabelle S. Brum, Jonathan Fragoso Miranda de Oliveira, Ana Clara S. Costa, Stella C. Duarte, Sarah Moon, Stefany de Castro B. Moura, Andressa P. de Oliveira, Nubia Boechat, Monica M. Bastos   +11 more
wiley   +1 more source